Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans

Daniel Higgins[1,2‡*], Joshua Looker[1,2‡*], Robert Sunnucks[1,2‡*], Jonathan Carruthers[3], Thomas Finnie[3], Matt J. Keeling[2,4], Edward M. Hill[5,6*]

1 EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, United Kingdom.
2 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom.
3 Data, Analytics and Surveillance, UK Health Security Agency, Porton Down, United Kingdom.
4 Mathematics Institute and School of Life Sciences, University of Warwick, Coventry, United Kingdom.
5 Civic Health Innovation Labs and Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
6 NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, United Kingdom.

‡These authors contributed equally to this work.

* Corresponding Authors. Emails: daniel.higgins@warwick.ac.uk; joshua.looker@warwick.ac.uk; rob.sunnucks@warwick.ac.uk; edward.hill@liverpool.ac.uk.

Abstract

Avian influenza A(H5N1) poses a risk to public health due to its pandemic potential should the virus mutate to become human-to-human transmissible. To date, reported influenza A(H5N1) human cases have typically occurred in the lower respiratory tract with a high case fatality rate. There is prior evidence of some influenza A(H5N1) strains being just five amino acid mutations away from achieving droplet transmissibility, possibly allowing them to be spread between humans. Three of these amino acid mutations must occur within a single human host, though the exact probability of such mutations occurring is not currently known. Here, we present a mechanistic within-host infection model for influenza A(H5N1), novel for its explicit consideration of the biological differences between the upper and lower respiratory tracts. These developments enable us to estimate a distribution of viral lifespans and effective replication rates in human H5N1 influenza cases. We combine our within-host model with a viral mutation model to determine the probability of an infected individual generating a droplet transmissible strain of influenza A(H5N1) through mutation. For three required mutations, we found a peak probability of approximately 10^{-3} that a human case of H5N1 influenza produces at least one virion during the infectious period. Our findings provide insights into the risk of differing infectious pathways of influenza A(H5N1) (namely the avian-human vs the avian-mammal-human routes), demonstrating the three-mutation pathway being a cause of concern in human cases. Additionally, our framework - combining a within-host infection model with a branching process model for viral mutation - is generalisable to other pathogens, allowing mutation probabilities to be more easily ascertained. Our findings are a starting point for further modelling of influenza A(H5N1) and other pathogens where differing tissue susceptibilities and human-to-human transmission is of concern.

1 Introduction

The influenza virus family is responsible for influenza infections (colloquially referred to as the 'flu') in a variety of animals including humans, other mammals and birds. There are four main influenza types (A-D); within type A influenza there is substantial public health concern around the avian influenza A(H5N1) subtype, commonly known as bird flu. Influenza A(H5N1), which we will refer to as H5N1 influenza, is highly pathogenic in avian species and considered panzootic, being widely distributed in wild and domesticated birds [1]. There have been 911 reported cases of human H5N1 influenza worldwide as of 23 May 2024 [2]. These reported cases have generally been severe, with a case fatality rate of 53% [3] although, at the time of writing, there is little evidence for human-to-human transmission of H5N1 [4]. Nonetheless, the high prevalence of the infection in the avian population is causing mounting concerns that under the right circumstances, an H5N1 strain could mutate to allow human-to-human transmission. If this were to occur, transmission between humans is likely to allow increased spread of the virus (at similar levels to the seasonal flu) with a resultant pandemic amongst humans.

Previous flu pandemics, and seasonal flu outbreaks, are primarily infections of the upper respiratory tract (URT) [5] due to the presence of $SA_\alpha 2,6$ receptors that these strains preferentially bind to for cell entry. H5N1 influenza, however, preferentially binds to $SA_\alpha 2,3$ receptors present in the avian respiratory and intestinal tracts [6–10], and these receptors are primarily found in the lower respiratory tract (LRT) in humans. This not only makes it much more difficult for initial human infection to occur, but also means that droplet transmission (the main source of seasonal flu transmission) is not viable, hence the current lack of human-to-human transmission of H5N1 influenza. However, with suitable mutations within humans, H5N1 influenza could evolve the ability to infect the URT as well as the LRT. This is cause for concern for two reasons. Firstly, infections in the LRT may lead to greater mortality due to increased risk of pneumonia and other related fatality risks [11]. Secondly, with the ability to infect the URT, human-to-human transmission becomes more likely, increasing the pandemic potential of H5N1 influenza [6, 8, 9].

From our present knowledge base it is believed that five amino acid substitutions in H5N1 influenza are required for human-to-human transmission to be possible, with two of these mutations having already been seen in viruses sampled from the avian population [6]. It is believed that the other three mutations are unlikely to evolve in avian species as they are deleterious to the virus in birds. Consequently, between three and five mutations are required to take place in humans for droplet transmission to be likely.

For pandemic preparedness, it is crucial that we have suitable tools available to quantify the chance of an infected individual generating a droplet transmissible strain of H5N1 influenza through mutation. However, the probability of such mutations in H5N1 influenza occurring within a human host is presently unknown. To enable modelling analysis of this problem, there are two key limitations in the existing modelling literature. The first is that previous models of H5N1 influenza within-host infection dynamics in humans do not take into account the differences between the two tracts (URT and LRT). Although there have been modelling efforts to account for the binding specificities of H5N1 influenza in different areas of the respiratory tract [7], and it is understood that fluid dynamic effects/having multiple patches impact contagion dynamics [12–14], to our knowledge no current research explicitly models H5N1 influenza infection dynamics in the LRT and URT. The second is that although potential mathematical frameworks for the modelling of advantageous mutations (such as those required for droplet transmissibility) do exist in the literature, these have explored the implications of the frameworks as opposed to explicitly finding the mutation probabilities [6, 15, 16].

In this paper, we present a combined modelling framework to address these two notable methodolog-

ical gaps. The first modelling component is a novel within-host two-patch (both upper and lower respiratory tract), ODE infection model for H5N1 influenza. By inferring patch-dependent disease parameters, we seek to capture the biological differences in spreading capability of H5N1 influenza in the two parts of the respiratory tract. The second modelling component is an enhanced branching process model (BPM) for H5N1 influenza virus mutation, building on the work of Russell *et al.* [6]. Informed by the within-host model outputs, and including the distribution of infection lifespans and real-time replication number estimates, we use the BPM to provide a more realistic estimate on the evolutionary dynamics of a human H5N1 influenza infection. Combined, our modelling framework is generalisable to other respiratory pathogens, allowing researchers to estimate the mutation chances for a pathogen mutating specific traits.

2 Methods

Herein we summarise the three main methodological components of our study. We begin with a description of the novel within-host deterministic infection model and its calibration to both the canonical H5N1 influenza dataset and case fatality rate (Section 2.1). This is followed by the introduction of the branching process model for viral mutation and how it incorporated the within-host model results (Section 2.2). Finally, we list the methods and model realisations used to calculate both the time dependent proportion of mutant virions in a host and the probability that a human-to-human transmissible strain could arise from an infection (Section 2.3).

To simulate the within-host infection model (and its proxies) and the branching process model we used Python 3.11 with packages: Numpy (version 1.26.4), Matplotlib (version 3.84), Scipy (version 1.13.0) and Pickle (version 4.0). We conducted the Approximate Bayesian Computation scheme for fitting the within-host model in R 4.3 using the packages: tvmtnorm (version 1.6), KScorrect (version 1.4.0) and deSolve (version 1.40). A repository containing the data and code used to conduct this study can be found at `https://github.com/joshlooks/avianflu`.

2.1 Within-host infection model explanation and fitting

Our within-host model for H5N1 influenza infection introduced key biological processes not present in other models in the literature. This model development subsequently forms the basis of the remaining results presented in this paper. Here we outline the canonical dataset used for fitting the intra-host model (Section 2.1.1), provide the biological description of the infection model (Section 2.1.2) and state the corresponding ODE system (Section 2.1.3). We then explain how the model parameters were calibrated using literature (Section 2.1.4) and an Approximate Bayesian Computation scheme (Section 2.1.5). Lastly, introducing mortality into our two-patch model was of utmost importance for informing how likely human-to-human transmission may be. The relatively high case fatality rate of H5N1 influenza could hamper its ability to mutate in the body since those infected may be likely to die before the virus has a chance to mutate to become human-to-human transmissible. We thus conclude this section by outlining how we fit the model outputs to mortality data (Section 2.1.6).

2.1.1 Data

We made use of the ubiquitous dataset in the literature corresponding to the viral titres of six hospitalised H5N1 influenza patients in Vietnam in 2004 and 2005 [17]. The titrations were formed from pharyngeal swabs taken daily after presentation at the hospital. These measurements corresponded to the viral load in the URT only, with viral loads varying in many orders of magnitude between patients on the same estimated day post infection (Fig. 1). We anticipated that this characteristic of the data, and the small, noisy sample, could pose issues around parameter identifiability and model

Fig. 1. Viral titres from pharyngeal swabs of hospitalised H5N1 influenza patients in Vietnam. Data from de Jong *et al.* [17]. We used this dataset to calibrate all models included in this paper.

generalisation to an 'average infection' during model fitting. Nonetheless, this dataset is the most recent and complete human infection data available for H5N1 influenza. Prior studies attempting to calibrate models to these data have gathered an understanding of related biological processes [7, 18]. It thereby provides an entry point for calibration of our proposed model and the exploration of its infection dynamics.

2.1.2 Deterministic two-patch infection model description

We first built a deterministic two-patch ordinary differential equation infection model, with the URT and LRT each having their own internal processes. The URT and LRT then interact via the diffusion of the free virus between each patch and an advection term, describing the movement of free virus between patches via physical movement of fluid. The advection term can be considered the transfer of mucus (through coughing or mucociliary clearance by cilia) from the LRT to the URT. A graphical depiction of the above processes is shown in Fig. 2.

For the within-patch processes (the cells subfigure in Fig. 2), we modelled each respiratory tract compartment as having a set of uninfected epithelial cells (or 'target cells', T) to which the H5N1 influenza virions (V) may bind. After infection by a virion, the cells move into an eclipse/latent phase (E) where they are infected by the virus but do not produce any additional virions. After an exponentially-distributed period of time, the cells leave the latent phase and enter the infected phase (I), producing free virions. LRT models for Influenza A have been studied previously; we based our more complex two-patch model on a model of the infection in the LRT by Handel *et al.* [19]. We note in particular that the key difference between the URT patch and the LRT patch is that it is generally considered that the URT can be modelled using a 'target-cell limited' approach. In other words, there is limited immune response in the URT and the dynamics of the virus are entirely governed by the number of uninfected cells alive. Thus, we only considered an immune response in the LRT patch. The adaptive immune response (X) has a humoral component comprised of B-cells and antibodies, as well as a cellular component, comprised of T-cells. The humoral component causes the IR to increase proportionally to the viral load in the LRT, and the clonal expansion of the T-cells causes the IR to

Fig. 2. LRT and URT explicit within-host respiratory infection model schematic.
Compartments listed are uninfected/target cells (T), free virions (V), eclipse/latent cells (E),
infected/virion-producing cells (I) and the adaptive immune response (X). Note that the subscripts
U, L represent the URT- and LRT-based compartments respectively. The different colours represent
the processes in the URT (in blue) and in the LRT (red). Arrows show the spread of the contagion
through the host. The dashed arrows in the virus compartment indicate the coupling of the two
patches through advection and diffusion. Parameters descriptions are found in Table 1.

grow exponentially, as in Handel *et al.* [19]. X can be considered to represent antibodies in the host.

2.1.3   ODE system

The within-host dynamics of H5N1 infection obeyed the following system of ordinary differential equations. We note that a subscript U denotes that the compartment / parameter is for the URT, while a subscript L denotes that the compartment / parameter is for the LRT.

$$\frac{dT_U}{dt} = -\beta_U T_U V_U$$

$$\frac{dE_U}{dt} = \beta_U T_U V_U - gE_U$$

$$\frac{dI_U}{dt} = gE_U - dI_U$$

$$\frac{dV_U}{dt} = p_U I_U - cV_U - \gamma\beta_U T_U V_U - D(V_U - V_L) + aV_L$$

$$\frac{dT_L}{dt} = -\beta_L T_L V_L$$

$$\frac{dE_L}{dt} = \beta_L T_L V_L - gE_L$$

$$\frac{dI_L}{dt} = gE_L - dI_L$$

$$\frac{dV_L}{dt} = p_L I_L - cV_L - \gamma\beta_L T_L V_L - kV_L X + D(V_U - V_L) - aV_L$$

$$\frac{dX}{dt} = fV_L + rX$$

with β_U and β_L the rate of infection in the URT and LRT, g the latent transition rate of infected cells, d the mortality rate of infected virus producing cells , p_U and p_L the virus production rate in the URT and LRT, c the morality rate of free virions, γ the conversion rate between infection and viral titre, f the recruitment rate of adaptive immune response, r the expansion rate of adaptive immune response and k the kill rate of adaptive immune response, D the rate of diffusion and a the rate of advection.

2.1.4   Model parameterisation from the literature

We obtained values from the literature for a subset of parameters in our ODE model. From Dobrovolny *et al.* [18], we set the latent state duration of infected cells ($1/g$) as 1/4 days, the lifespan of infected virus producing cells ($1/d$) to be 1/5.2 days and the lifespan of free virions ($1/c$) as 1/2 day. We also highlight that Dobrovolny *et al.* [18] noted that their values were consistent with other research in the area.

For the immune parameters, we took the approach found in Handel *et al.* [19]. Although this was fitted to mice data, studies have shown that the mice immune system is a suitable analogue for the immune system found in humans *in vivo* [20]. Further, parameters are likely transferable through the comparison of mice and human metabolic rates - mice have a metabolic rate seven times that of humans [21]. We converted from plaque-forming unit (pfu) into TCID$_{50}$ (Tissue culture infectious dose 50%), with pfu being proportional to TCID50 by a factor of 0.56 [22].

It was also important to select an initial number of target cells and initial viral load. We took the estimated values of $T_U = 4 \times 10^8, T_L = 6.25 \times 10^9$ from Ciupe and Tuncer [23], which were calculated using the average surface area of an epithelial cell and of the human respiratory tract. We took the initial viral load ($V_0 = 1.3 \times 10^3$ TCID$_{50}$/ml) from the fitted values of the single-target-cell model in Dobrovolny *et al.* [7].

There was little information in the literature regarding rate of infection β_U and β_L, virus production rate p_U and p_L, conversion rate between infection and viral titre γ, rate of diffusion D or rate of advection a. These parameters of interest were also chosen as they have been found to have the biggest impact on the observed disease dynamics [7, 14, 18]. It is also worth noting that setting $\gamma = 0$ leads to similar results (and is normally ignored in human models [14, 18, 19]). This parameter represents the conversion rate between the viral titre (in TCID$_{50}$) and the number of free virions used to infect a target-cell. Setting this parameter to zero indicates that there is no noticeable change in the viral titre due to the infection of target-cells. By re-introducing this parameter (allowing it to be non-zero), we gained an extra degree of freedom in the model that allowed for more biologically realistic parameter values and peak shapes to be observed during parameter fitting.

We state the default model parameters, for non-fitted parameters, in Table 1. Some of the selected parameter values are similar to literature values for models fitted to H1N1 infection data within humans [24–26]. However, previous studies on H5N1 influenza infection in humans found that these values gave good fits to the data, and that the other aforementioned parameters that we fitted for were the main contributors to viral dynamics [7, 18].

2.1.5 Model calibration and parameter inference

To calibrate the model, we made use of the dataset outlined in Section 2.1.1. We note that this corresponds to the viral load in the URT only, and so we could only fit the model dynamics based on this compartment. Parameter identifiability is a problem for most mathematical biology models, and this was especially true for our fitting process as we have less than 20 data points available, all of which correspond to hospitalised individuals who died from the infection.

To fit the parameters we employed an Approximate Bayesian Computation Sequential Monte Carlo M Nearest Neighbours (ABC-SMC-MNN) method based on the pseudo-code found in Minter and Retkute [27], using methods originally developed by Filippi *et al.* [28] and Toni *et al.* [29]. Due to the lack of data, and its continuous nature, an exact likelihood function for data fitting is difficult to justify, thus we adopted an ABC inference scheme. With large order of magnitude differences across our data points, we chose the summary statistic (c) to be the model error on a log-scale, where y is the data, N is the number of data points and x is the model predictions:

$$c = \sum_{i=1}^{N} \left(\left(\log \left(y_i \right) \right) - \log \left(x_i \right) \right)^2$$

We chose the perturbation kernel to be a truncated-multivariate-normal distribution (truncated to take into account the prior). For the prior distributions, we assumed log-uniform prior distribution for all variables (see Table 1 for the prior distribution ranges). We selected log-uniform priors as it is an uninformative prior and because the parameters were likely to be skewed towards lower orders of magnitude (such that our prior belief was the parameters being uniform on a log-scale). We informed the parameter ranges of the priors by first taking a least-squares fit (to both the normal and log-scale data); we then took a wide range around those values to define the prior bounds. Furthermore, we also assumed the spreading rate in the LRT (β_L) to be greater than that in the URT (β_U). This

Table 1. List of parameters and their descriptions. For fixed parameters we state their value and associated references. For inferred parameters we list their prior distribution (we use *lU* as a notation for the log-uniform distribution). We provide unit information for each parameter in parenthesis after the parameter description.

Parameter		Value	Prior
β_U	Rate of infection, URT (day^{-1})	-	$lU(1 \times 10^{-8}, 1 \times 10^{-6})$
β_L	Rate of infection, LRT (day^{-1})	-	$lU(1 \times 10^{-7}, 1 \times 10^{-5}$
$1/g$	Productively infected cells (days)	1/4 [18]	-
$1/d$	Lifespan of infected, virus-producing cells (days)	1/5.2 [18]	-
p_U	Virus production rate, URT (day^{-1})	-	$lU(1 \times 10^{-4}, 1)$
p_L	Virus production rate, LRT (day^{-1})	-	$lU(1 \times 10^{-4}, 1)$
$1/c$	Lifespan of free virions (days)	1/2 [18]	-
γ	Conversion between infectious virions and TCID$_{50}$ / PFU (unitless)	-	$lU(1 \times 10^{-6}, 2 \times 10^{-3})$
f	Recruitment rate of adaptive immune response (day^{-1})	$0.56 \times 2.8 \times 10^{-6}/7$ [19] (fig 6)	-
r	Expansion rate of adaptive immune response (day^{-1})	0.27/7 [19] (fig 6)	-
k	Kill rate of adaptive immune response (day^{-1})	20 [19]	-
D	Rate of diffusion of free virions (day^{-1})	-	$lU(1 \times 10^{-3}, 1)$
a	Rate of advection (day^{-1})	-	$lU(1 \times 10^{-3}, 1)$

is because H5N1 influenza preferentially binds to proteins more commonly found in the LRT as the type of receptor expression in the LRT is more similar to the avian respiratory tract [7, 30–32]. The chosen hyper-parameters for the algorithm were to run the method adaptively, with an error tolerance in the first generation of 150. The error tolerance for subsequent generations was then set at the 40$^{\text{th}}$ percentile of the previous generations' particles. We set the algorithm to terminate either after 10 generations, or when the error tolerance changed by less than 1% between subsequent generations. The algorithm converged after four generations, with a final (adaptive) error threshold of 121.2 (compared to a 121.8 tolerance in generation three). The error threshold in the final generation had similar error to the least-squares fit value of 120.9.

2.1.6 Mortality

It is currently believed that a leading cause of death amongst H5N1 influenza patients is a phenomenon known as a 'cytokine storm' [33]. This occurs when the immune response to the virus is elevated to the point where the body overwhelms itself, causing massive inflammation and ultimately death [34].

Since a cytokine storm results from the immune system's sustained response to viral load, for our

two-patch model we took cumulative viral load as a proxy for mortality. In particular, we considered the integral of the logarithm of the viral load over time as our metric for mortality:

$$\int_0^t \log\left(V_U(s) + V_L(s)\right)ds > M$$

with M a constant. To determine the value of M, we took the case fatality rate of 53% given in Sah *et al.* [3] and found the value of M that corresponded to said case fatality rate from the results of our stochastic simulations. In doing so, we set $M = 119.890$.

We also conducted a sensitivity analysis of our results to a lower case fatality rate of 20%. This value was taken from Dobrovolny *et al.* [18] for individuals treated with neuraminidase inhibitors and lead to a higher M value of 153.092.

Introducing the proxy for mortality given above, we calculated the total length of infection for each of our infection simulations. We considered the infection to be finished when either a patient dies or their total viral load fell below $V_U + V_L < 10^4$, i.e.

$$T = \sup_t\{t \in \mathbb{R}^+ : \mathbb{1}_{\{\text{patient alive}\}}(t)[V_U(t) + V_L(t)] > 10^4\}$$

From this, we calculated an empirical distribution for T that we used to model viral mutations within humans (Fig. 3(a)). When taking a case fatality rate of 53%, most of the empirical distribution for T occurred between eight to ten days post infection, having reasonable correspondence to previously recorded infections of (and modelling efforts for) H5N1 influenza infections lasting for around ten days [6, 7, 18]. When instead assuming a case fatality rate of 20%, most of the empirical distribution for T was between eight and twelve days (Fig. 3(b)).

(a)   **(b)**

Fig. 3. Viral lifespan (T) distributions under each case fatality rate assumption. The assumed case fatality rates were **(a)** 53% and **(b)** 20%, respectively. We obtained the viral lifespan distributions by determining when either the viral load dropped below 10^4 or the integral under the log curve reached a value M. We performed the fitting method outlined in Section 2.1.6.

2.2 Mutation modelling and viral dynamics

From outputs that could be generated from our two-patch within-host model, we next needed an additional modelling component that would enable us to calculate the proportion of virions with zero, one, two, three, four and five mutations, and the probability that any given virion within the body had this number of mutations. In this section we outline our adapted stochastic branching process mutation model used for this purpose. This model contains biologically informed values for key model parameters, informed by the incorporation of results from the within-host infection model, thus providing a prominent modelling advance.

We adapted the stochastic branching process mutation model for viral mutation introduced in Russell *et al.* [6], in which viral replication occurs at fixed time intervals of length Δ with a mutation rate μ and replication rate r. The total number of viruses with j mutations at each time step $t_k = k\Delta$ (with $k \in \mathbb{N}$ and $t_k < T$), $N_{t_k}^{(j)}$, is then given as a Poisson random variable:

$$N_{t_k}^{(j)} \sim \text{Poi}(r \sum_{i=0}^{5} N_{t_{k-1}}^{(i)} \mu_{ij})$$

where

$$\mu_{ij} = \mathbb{P}(\text{Mutates from } i \text{ to } j \text{ mutations}) = \begin{cases} \mu^{j-i} \text{ for } i < j \\ 1 - \mathbb{1}_{\{i < 5\}} \sum_{j=i+1}^{5} \mu^{j-i} \text{ for } i = j \\ 0 \text{ otherwise} \end{cases}$$

Note that the rate of $N_{t_k}^{(j)}$ is a summation due to the additive property of the Poisson random variable.

We adapted the above process to allow for model parameters to be informed from the fitted within-host infection model. We allowed r to be a function of time, $r(t_k)$, rather than a fixed value. Our branching process was thus instead defined by:

$$N_{t_k}^{(j)} \sim \text{Poi}(r(t_k) \sum_{i=0}^{5} N_{t_{k-1}}^{(i)} \mu_{ij})$$

The function $r(t_k)$ represents the viral replication rate as derived from our two-patch within-host model. To define it, we first express a partition P of $[t_k, t_{k+1}]$ such that $t_k = \tau_0 < \tau_1 < \cdots < \tau_m = t_{k+1}$ with $\tau_{i+1} - \tau_i = \delta$ where δ is the rate at which the ODE system is updated when solved numerically. It is then given by the product of the weighted sum of the number of virions created and destroyed at each time step δ in each tract:

$$r(t_k) = \prod_{l=1}^{m} \frac{\sum_{S \in \{U,L\}} R_{\tau_l}^{(S)} K_{\tau_l}^{(S)} V_{\tau_{l-1}}^{(S)}}{V_{\tau_l}}$$

which is dependent on these four functions (with $S \in \{U, L\}$, denoting whether the value corresponds to the URT or LRT and $N, V, D, p, I, c, V, \beta, T, k, X$ and V are as described in Section 2.1.3):

The growth rate of new virions $\quad R_{\tau_l}^{(S)} = 1 + \dfrac{N_{\tau_l}^{(S)} - N_{\tau_{l-1}}^{(S)}}{V_{\tau_{l-1}}},$

The death rate of existing virions $\quad K_{\tau_l}^{(S)} = 1 - \dfrac{D_{\tau_l}^{(S)} - D_{\tau_{l-1}}^{(S)}}{V_{\tau_{l-1}}},$

The rate of virion production $\quad \dfrac{dN^{(S)}}{dt} = p^{(S)}I^{(S)},$

The rate of virion removal $\quad \dfrac{dD^{(S)}}{dt} = cV^{(S)} + \beta^{(S)}T^{(S)}V^{(S)} + \mathbb{1}_{\{S=L\}}kXV^{(S)}.$

2.3 Mutant virion proportions and probabilities

Our final piece of analysis involved exploring the time dependent proportion of mutant virions in a host and the probability that a human-to-human transmissible strain could arise from an infection. H5N1 influenza requires five mutations to achieve droplet transmissibility between humans. Previous studies have found that up to two of the required five mutations can naturally occur in birds [6]. Depending on the number of mutations that have occurred prior to the human H5N1 influenza case, mutant virions then require either three out of three, four out of four, or five out of five of the required mutations for droplet transmission. Results from the branching process model allowed us to inform the probability that at any given time during the infection, the human host has at least one virion with the necessary number of mutations required for human-to-human transmission. Note that we term "X out of X mutations" for instances where the required total five mutations to achieve droplet transmission could be obtained during the infection episode of the human case (i.e. acquiring three or more mutations during the human infection case episode).

We ran the branching process model for viral mutation over the 1000 posterior predictive trajectories acquired via the procedure outlined in Section 2.1.5. We initialised the starting viral load as 10^6 virions in each realisation. Our reasoning for that choice is as follows. The initial viral count in our two-patch within-host model was 1.3×10^3 TCID_{50}/ml. For influenza A virions, the viral count per ml is around four orders of magnitude greater than the TCID_{50}/ml value [35]. Using these two pieces of information, this gave us a viral density of approximately 10^7 virions per ml. Then, taking an initial infected droplet of size 10^{-1}ml, we arrive at an initial viral count of 10^6 virions. In these simulations we also took Δ (the period between replications) to be six hours, noting that δ (the update rate of the two-patch within-host model solutions) is 0.001 days. This corresponds to the virions making two replication cycles (one from cRNA to vRNA and then back to cRNA) every 0.5 days, as in Russell *et al.* [6].

We ran two sets of simulations of the branching process model. The first was a set of one million BPM realisations (1000 copies of each of the 1000 sets of parameter samples in the posterior distribution), seeding the infection with an initial viral load of 10^6 virions.

The second was a set of 1000 BPM realisations (one for each of the parameter sample sets in the parameter posterior distribution) with $10^6 \times 10^6$ initial virions (to simulate one billion people, but combining BPMs to save on computation time). This provided a higher precision in the calculation of mutation virus proportions.

We also calculated the probability that an individual had at least one virion exhibiting a specific number of mutations. This provided another indication of the likelihood of an infection mutating to allow for human-to-human droplet transmission. This probability calculation was, however, intractable for the BPM that simulated one billion people as it required being able to differentiate between individuals (not possible here as we combined BPMs as it is computationally expensive to run the number of individual realisations needed to achieve the required level of precision). We thus introduced

an upper-bound estimate for this probability at time t. Using this approximation allowed for a probability approximation to be produced for a much higher number of BPM realisations.

The approximation was as follows. Let V_t be the (mean) virion count for an individual at time t, and $V_t^{(i)}$ be the (mean) number of virions with i mutations for an individual at time t. Additionally, given an (average) infected individual, let A be the event that this individual has no virions with i mutations at time t and B_k be the event that virion k in this individual does not have i mutations at time t, where $k = 1, 2, ..., V_t$. Then,

$\mathbb{P}(\text{An individual at time } t \text{ has at least one virion which has undergone } i \text{ mutations})$

$= 1 - \mathbb{P}(A)$

$= 1 - \mathbb{P}(\bigcap_{k=1}^{V_t} B_k)$

$= 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k \mid \bigcap_{j<k} B_j)$

$\leq 1 - \prod_{k=1}^{V_t} \mathbb{P}(B_k)$

$= 1 - \prod_{k=1}^{V_t} (1 - \dfrac{V_t^{(i)}}{V_t})$

$= 1 - (1 - \dfrac{V_t^{(i)}}{V_t})^{V_t} = \hat{p}_t^{(i)}, i = 0, 1, 2, 3, 4, 5$

To justify the inequality, we first note that if an arbitrary virion at the current timestep has i mutations, the probability that any other virion has that number of mutations would increase. This is because there is a chance that virions with the same number of mutations could have the same parent. The joint probability events $(B_k \mid \bigcap_{j<k} B_j)$ takes into account this positive correlation (but the event B_k by itself does not), i.e. $\mathbb{P}(B_k \mid \bigcap_{j<k} B_j) \geq \mathbb{P}(B_k)$

Additionally, since each virion is equally likely to mutate, we used the proportion of virions with i mutations to get that $\mathbb{P}(B_k) = 1 - \dfrac{V_t^{(i)}}{V_t} \quad \forall k$.

3 Results

3.1 Fitting the two-tract within-host respiratory infection model to H5N1 influenza viral titre data

Having developed our within-host respiratory infection model, with infection dynamics in the LRT and URT modelled explicitly, it was important to ascertain whether it could reproduce the observed H5N1 influenza viral titres (Fig. 1) whilst maintaining biologically reasonable parameters. Resultant parameter posteriors would then be used as inputs to the branching process model.

We ran the ABC-SMC-MNN routine and obtained 1000 samples of the posterior distribution for seven fitted parameters: β_U, β_L, p_U, p_L, γ, D and a (Fig. 4). We note that even for the posteriors that had similarities to a log-uniform distribution ($\beta_L, p_L, \gamma, D, a$), the range and probability mass of these distributions shifted compared to the prior. This is reinforced by a least-squares fit producing a similar profile to the median of the posterior-predictive distribution (Fig. 5(a)). The least-squares fit parameters can be found in Section S1.

Comparing the inferred posterior distributions for the URT and LRT spreading rate parameters, the 95% credible interval for the spreading rate in the URT ($\beta_U \in [2.47 \times 10^{-7}, 5.85 \times 10^{-7}]$) was at a lower range than in the LRT ($\beta_L \in [1.10 \times 10^{-7}, 6.56 \times 10^{-6}]$). This difference possibly corresponds to the preferential binding of H5N1 influenza to the epithelial cells in the LRT than in the URT. The production rate in the URT ($p_U \in [0.184, 0.568]$) was higher than in the LRT ($p_L \in [0.0005, 0.070]$), likely due to the higher target-cell count (and thus maximum production rate) in the LRT. There was a clear negative correlation between β_U and p_U (relating to the previous discussion), which is to be expected as an increase in the spreading rate would lead to target-cells being infected sooner and hence a larger infection time available to produce virions (meaning that a lower p_U is required) and vice-versa. The 95% credible interval for γ was at a low range of $[2.07 \times 10^{-6}, 1.90 \times 10^{-4}]$, indicating that the parameter was needed to delay the peak time, but only at smaller values. The 95% credible intervals for the diffusion ($D \in [0.002, 0.666]$) and advection ($a \in [0.002, 0.130]$) coefficients are quite wide, possibly indicating that the intra-patch processes contribute more to the total viral dynamics.

Through simulation of our model using the 1000 parameter sets representing samples from the target posterior distribution, we next checked the correspondence between the posterior predictive distribution for V_U and the empirical viral titre data (Fig. 5(a)). The predictive interval lay within the middle range of the dataset. The qualitative shape (including peak height and time) of the median was very similar to other models [7, 14, 18, 36]. We note that although some of the data points did not fit within the prediction interval, this was due to the many orders of magnitude difference in the different viral titre curves between patients on the same day post infection (Fig. 5(b)). Furthermore, the trajectory resulting from parameters obtained via a least-squares optimisation approach (Section S1) resided within the 99% posterior predictive interval. For the least-squares optimisation five different starting parameter sets were chosen and the resultant local mode with the lower error was selected. Although not guaranteed, we are confident that this is likely the global optima as multiple starting points converged to this value. This outcome supports the parameter posterior distributions acquired by the ABC approach successfully incorporating the posterior.

Lastly, inspection of the peak time distribution of viral titre realisations from the posterior predictive distribution showed almost all of the density of peak viral titre occurring between 4 and 5.5 days post infection (Fig. 5(c)). This observation provided further assurance in the concordance between the fitted model and the empirical data.

Fig. 4. Parameter posterior distributions. We obtained 1000 samples of the target posterior distribution using the ABC-SMC-MNN method outlined in Section 2.1.5. Diagonal panels show the marginal distributions for: rate of infection in the URT (β_U) and the LRT (β_L), virus reproduction rate in the URT (p_U) and the LRT (p_L), conversion rate between infection and viral titre (γ), rate of diffusion of free virions (D) and the rate of advection (a), respectively. Off-diagonal panels show bi-parameter distributions, where the contour shading intensity corresponds to the probability density value (lighter for higher probability density). Parameters (β_L, p_L) in the LRT tended to be higher than the URT (β_U, p_U), agreeing with the biological preference for H5N1 influenza to infect the LRT.

3.2 Viral dynamics and branching factor by survival status

Having acquired posterior predictive trajectories for the viral load, we fit the resultant values using the mortality proxy (Section 2.1.6). This process allowed for the separation of simulated stochastic viral dynamics into individual who cleared the infection and those who died (Fig. 6(a)).

Noting that the virion count is proportional to the viral titre (and so should follow the same dynamics), we can see that the median shape of the BPM is similar to the median of the within-host ODE model (Fig. 5(a)). We do see high peaks for a small number of individuals early in the infection, with 11.3% of all realisations peaking in days 0-4, with these trajectories arising due to stochasticity. In the initial days post infection, the simulations have not had time for the instantaneous replication rate to 'average out' over time. Thus, at these early times, the range of viral load is much higher. We also see that individuals with an earlier peak in viral load are those who survived infection. Indeed, while their peak is higher, the infection dies off much earlier, and so they do not get such a sustained viral load (and thus the area under the curve in the mortality proxy, is lower). Individuals who exhibited a slightly later peak and were then unable to fight off the infection quickly died.

For the posterior distribution of replication rates ($r(t)$) trajectories, in the majority of realisations $r(t)$ between days zero and four is essentially constant (Fig. 6(b)), corresponding to the exponential growth of v (Fig. 6(a)). A handful of trajectories exhibited very high values, again, due to early stochasticity. In particular, individuals who died as a result of infection saw a less steep decrease in $r(t)$ after four days, corresponding to the more sustained viral load exhibited (Fig. 6(a)).

Studying the relationship between viral lifespan and peak replication rate ($r(t)$), there was a strong negative correlation between the two variables (Fig. 7). Infections with a smaller peak value of $r(t)$ exhibit a much more sustained period of infection. Similar to what was observed in Fig. 6(a), individuals with a smaller but sustained $r(t)$ are more likely to die from the disease (due to a higher area under the curve). As a consequence, the maximum length of time an individual was likely to be infected for in the within-host model was around 10 days. After this amount of time post infection, individuals have either fought off the virus, or died as a result of their infection.

When instead considering a case fatality rate of 20%, with individuals on average surviving longer given a lower case fatality rate, the range of viral lifespan became broader and reached up to 14 days (Fig. S1. This contrasted to the viral lifespan distribution obtained in our main analysis (using a case fatality rate of 53%), with more individuals being overwhelmed and dying, or alternatively clearing the virus after around 10 days (Fig. 3(b)). Despite these changes to the viral lifespan distribution, we observed similar viral dynamics. In particular, the peak time of infection was unaffected as decreasing the fatality rate merely meant that the individual trajectories were simulated for longer before they either drop to the point where we consider the individual no longer infected or the infected individual dies.

Fig. 5. Posterior predictive distributions. (a) Posterior predictive distribution for V_U compared to the empirical data. We produced the posterior predictive distribution using the 1000 parameter samples from our inferred parameter posterior distribution in Fig. 4. We display the median (blue solid line), 99% pointwise prediction interval (shaded region) and the least-squares fit (dotted red line). Both the optimisation fit and ABC posterior show reasonable concordance to the main data trends. **(b)** As for **(a)**, but showing all posterior predictive trajectories as opposed to the distribution summary. **(c)** Posterior viral titre peak-time distribution showing that the majority of infections peak around day five. This is consistent with the data which shows a peak around day five to day six (post infection).

Fig. 6. Posterior predictions for $v, r(t)$. Both plots show the 1000 posterior trajectories, with the blue lines representing H5N1 influenza patients who survive the infection (cleared the virus) and the red lines representing patients who died due to the infection (where the distinction is made using the method in Section 2.1.6). **(a)** Virion count distribution found using the parameter posterior in Fig. 4. The viral count trajectories for deceased patients are lower and more sustained than surviving patients. These were calculated from the one million BPM realisations each with an initial viral load of 10^6 and a mutation chance of 10^{-5} per replication. **(b)** Distribution of $r(t)$ calculated from the posterior predictive distribution shown in Fig. 5(a). Surviving patients tended to have higher $r(t)$ in the first 4 days of infection, which then declined below one(indicating a decreasing virion count) more rapidly than for dying patients.

Fig. 7. Maximum r value vs viral lifespan. We observe a strong negative correlation between maximum r value and the viral lifespan. Maximum r values taken from Fig. 6(b) and corresponding viral lifespans are shown in Fig. 3. Blue circles represent H5N1 influenza patients who survive the infection (cleared the virus). Red circles represent patients who died due to the infection (where the distinction is made using the method in Section 2.1.6). Surviving individuals tended to have higher maximum $r(t)$ values.

3.3 Human-to-human transmission probabilities

With estimates for the viral lifespan distribution and effective replication number from the parameter posterior distribution, we used our BPM to investigate viral mutation dynamics. Recall that we performed two sets of BPM realisations: one set with one million BPM realisations (1000 copies of the 1000 sample sets in the posterior parameter distribution) that each had an initial viral load of 10^6 virions; a second set with 1000 BPM realisations (one for each sample comprising our parameter posterior distribution) that each had an initial viral load of $10^6 \times 10^6$.

From the first set of one million BPM realisations (see Section 2.3) we calculated the proportion of mutant strains over time (Fig. 8(a)) and probability of having at least one virion with x mutations over time (Fig. 8(b)). We found that virions with the required number of mutations for human-to-human transmission (three or more) made up a very small proportion of the viral load - around five orders of magnitude less than the strain with the next smallest proportion.

The derived probability approximation (Section 2.3) gave a generally sound upper bound, following a similar shape as the exact probability. A couple of exceptions were when a mutation first occurred and when the virus population died off near the end of the infection (Fig. 8(b)). This reflected the dependence on the population of other mutants being more pronounced at lower numbers of virions (where the presence of a four mutation strain, for example, is almost purely from mutations from zero, one, two, three strain virions). When a strain reaches 'persistence levels' within the total population, the estimate as an upper bound is more robust as the majority of each strain comes from the replication of said strain (and not via mutation). We note that the probability of at least one virion having the required four out of four mutations is zero for almost all of the infections simulated, apart from the time period between five and seven days where two out of the one million BPM realisations had at least one virion with these mutations before both strains died out.

The set of BPM realisations with a higher starting load (of $10^6 \times 10^6$ initial virions) allowed for a more precise computation of the proportion of mutant virions (Fig. 8(c)). Although some virions mutated further along the pathway to droplet transmission (compared to the realisations with a lower initial viral load), they only made up a very small proportion of the total virion count. Similarly, for the estimates of the probability of observing at least one mutant with the required number of mutations (Fig. 8(d)), probabilities of obtaining either four or five required mutations for droplet transmission were very low across the entire infection duration.

In the case where we considered a lower case fatality rate of 20% (rather than a case fatality rate of 53%), we observed similar mutation probabilities (Fig. S3). As expected, by lowering the case fatality rate the overall viral dynamics remained near identical for the majority of the infectious period. As such, the mutation probabilities were not affected until the end of the infection, by which point the peak of the mutation probabilities had already occurred.

Fig. 8. Mutated virion statistics with respect to time elapsed post infection, computed from BPM realisations. Line shading corresponds to the number of mutations (one mutation the lightest shading through to five mutations being the darkest shading). In all BPM simulations we fixed the probability of mutation at 10^{-5} per replication. In panels **(a&b)**, each realisation had an initial viral load of 10^6. We ran 1000 realisations of each of the 1000 posterior parameter sets (Fig. 4). In panels **(c&d)**, each realisation had an initial viral load of $10^6 \times 10^6$. We ran one realisation of each of the 1000 posterior parameter sets (Fig. 4). **(a,c)** Proportion of total virions with the specified amount of mutations. There were a very small proportion of virions that have the required number of mutations to achieve droplet transmission (three or more mutations). **(b,d)** Probability of having a mutation strain. We present the estimated probabilities as the dashed lines with circle markers. We present the actual probabilities as solid lines. Probability estimate derivation follows that given in Section 2.2. The estimated probabilities are a clear upper bound on the true probabilities. Depending on the number of mutations in the initial infecting virions, there was a low probability of achieving the required number of mutations near the beginning on the infection lifespan (which would allow more replication of the mutant strains).

4 Discussion

This paper presents a novel two-patch within-host model for an H5N1 influenza infection in a human host. Compared to existing literature, we explicitly model the lower and upper human respiratory tracts; this formulation enables us to mechanistically model the different biological responses to the infection in each tract. We also extend the earlier work of Russell *et al.* [6] to allow for more realistic modelling of virus mutations within a host. With these modelling developments we explored the risk of developing a human-to-human transmissible form of H5N1. Together these methods provide a general framework for combining within-host infection and within-host mutation models, which may be readily adapted to other (primarily respiratory) contagions.

The fitted within-host model displayed a preference for H5N1 influenza to spread in the LRT compared to the URT. This finding conforms with biological observations of a greater ease of spread for H5N1 influenza in the LRT (compared to the URT) [7, 8]. Also evident was the multi-modal nature of URT parameter posteriors. This is likely due to the URT behaving like a target-cell-limited model, in that the spread is only limited by the population of target-cells (as all of them become infected). Contagion dynamics are therefore less sensitive to the parameter values in the URT, resulting in the multi-modality of the parameter posterior distributions. Due to the higher target-cell numbers in the LRT, once the virus reaches the LRT the dynamics are much more sensitive to these parameters (β_L, p_L). As a consequence, the posterior has a much tighter peak around the mode. As previously stated, the qualitative shape of the median posterior predictive trajectory for viral titres in the URT is very similar to other models found in the literature [7, 14, 18, 36].

The analysis of the relationship between maximum effective replication number/growth rate, and peak viral load and infection lifespan revealed a negative correlation between these two variables. For the majority of instances where peak viral load was predicted to occur before day four, there was a second, smaller peak later in the period of infection at around day four, which previous studies have indicated are to be biologically expected [19]. Under our default modelling assumptions all posterior predictive viral lifespans were less than 11 days. This is in agreement with the scenarios presented in Russell *et al.* [6], where they take the length of infection to be 10 days.

The modifications we made to an existing BPM for viral mutation, namely incorporating time-dependent replication rates and a realistic infectious duration distribution, gave comparable results to Russell *et al.* [6]. As the upper bound on the probabilities (of having at least one virion with x mutations) were of extremely low orders of magnitude, it seems highly unlikely that a typical human infection would lead to the arrival of a strain with four or five mutations. There is a much higher probability of having at least one virion with the (minimal) required three mutations, which may indicate that, with a large enough outbreak, we would expect a human-transmissible strain to evolve within at least one individual. Nonetheless, the proportion of virions with this strain is still expected to be very low and so transmission of such strains (even if present) is unlikely [6]. In contrast, strains with one or two mutations were generally highly prevalent amongst the virion population. Current outbreaks in mammals (in particular the large number of infections in the US dairy industry [37]), whose respiratory tracts are more similar to humans than avian species, may mean that human secondary infections from these animal cases are caused by a strain that is further along the mutation pathway to droplet transmissibility. Thus, there may be a higher than modelled risk of reaching the required number of mutations if a human is infected by a strain transmitted from other mammals, rather than birds. Russell *et al.* [6] considers differing initial mutations and also differing fitnesses of mutant strains. They conclude that although this does increase the proportions and probabilities stated, they are still sufficiently small such that these changes are unlikely to lead to a meaningful increase in the probability of human-to-human transmission, with which we concur.

Our work has not considered the probability of virions in the respiratory tracts being present in exhaled droplets and instead focused on the probability of mutating a droplet-transmissible variant. Consequently, the probabilities present in this paper are not equivalent to the probability of any H5N1 influenza infection in a human leading to a droplet transmissible virus. Nonetheless, our work does provide a framework for making this calculation. In the future, the development of a proxy or a further calculation from the results presented is required to make a conclusion on this transmission probability. In principle, any time that $p_t^{(i)} > 0$, there is a chance of human-to-human droplet transmission, with higher proportions of mutant strains corresponding to a higher likelihood of droplet transmission, though the exact relationship between these two entities is unclear. Our results show that it is unlikely, albeit not impossible, that a human infection of H5N1 influenza could lead to onwards transmission of a droplet transmissible strain. The probability results indicate that the presence of previous mutations at infection onset are more worrying than the development of the strain through mutations, as this would provide more time for a droplet transmissible strain to reach persistence levels in a host. Droplet transmissible strains mutating earlier in the infection pose a more significant threat as early mutations lead to higher proportions of mutant strains within the individual throughout the length of infection. Furthermore, an early mutation is likely to correspond with a longer period in which an infected individual is symptomatic with said mutant strain, and this leads to a higher probability of this mutant strain being droplet transmitted to another human.

The model we have presented is necessarily a simplified representation of reality. It is important that we consider the modelling assumptions made and their potential limitations. Here we elaborate on the implications of: the quality of the dataset used, estimation of the infection fatality ratio, estimation of the infection duration and initial viral load assumptions.

We note that there may be multiple issues with the data. Although our two-patch posterior predictions are very similar to other fitted models [7, 14, 18, 36], all within-host models for H5N1 influenza spread in human hosts that use this dataset suffer from a lack of parameter identifiability and biological certainty. In particular, due to the small size of the dataset, and because all individuals died (even when given neuraminidase inhibitors), the average viral load may be much lower and viral lifespan much longer than is shown in our model. That being said, at the time of writing this dataset is the most recent and complete human infection data available for H5N1 influenza, providing an initial basis for the exploration of the effects of our novel two-tract within-host infection model.

With regards to the estimation of the infection fatality ratio, at the time of writing, recorded cases are primarily hospitalisations and are therefore more likely to result in fatalities than unrecorded infections. Indeed, individuals could have been infected with H5N1 influenza and exhibited seasonal flu-like symptoms, or been asymptomatic. More recent studies also estimate a larger seroprevalence of H5N1 influenza in humans than previously calculated, implying that the actual fatality rate of an H5N1 influenza infection is lower than previously thought [38–40]. We assumed a default value for the infection fatality ratio of 53%, based on the reported case fatality ratio, which is therefore likely to be an overestimate. Nonetheless, our sensitivity analysis with a lower infection fatality ratio gave similar qualitative conclusions. Further infection data for H5N1 influenza viral titres in humans would be required for more accurate modelling estimates and conclusions. It is important that new cases are thoroughly documented, such that future H5N1 influenza models have improved accuracy, especially at the beginning and end of the infection dynamics.

The third form of limitation relates to how pharmaceutical measures could impact the infectious duration of those infected with H5N1 influenza. Treatments, such as antivirals and neuraminidase inhibitors can reduce the viral load in individuals infected with H5N1 influenza exist and have been shown to be effective [18, 41, 42]. If infection with H5N1 influenza was caught early on then hospitalised

individuals could be treated, with the resulting lower mortality rates and longer infection lengths 526
plausibly leading to higher than estimated probabilities of obtaining a droplet transmissible strain 527
(similar treatments for COVID-19 patients led to higher mutation chances [43]). We note however, 528
that in the dataset used, all individuals who presented with H5N1 influenza were subsequently given 529
neuraminidase inhibitors, and yet all died due to their infection. Thus, it may be that in the majority 530
of individuals, such treatments do not produce any meaningful increase in duration of infection of 531
H5N1 influenza in humans. 532

Lastly, we had to make an assumption about initial viral load (which we fixed as 1.3×10^3 TCID$_{50}$/ml). 533
Given, the infection data used is primarily centred around the peak of infection, our inference is most 534
strongly determined by this peak behaviour. As a consequence, the early growth rate corresponds to 535
parameter estimates that give the 'correct' peak height and time for the data, given the assumed initial 536
viral load. A change in this viral load would change the growth rate with a negative correlation to the 537
initial viral load. Nonetheless, the viral lifespan distribution should be similar (as it is a function of the 538
peak time and area under the curve, which should not be affected much by the early rates of growth). 539
For the mutations model, a change in the initial viral load would result in the same proportions (as 540
they are primarily dependent on the mutation probability) as shown in our results. However, the 541
curves for mutant strain *probabilities* would be shifted up and towards the left such that there are 542
increased probabilities of observing strains with higher numbers of mutations earlier in the infection. 543

In addition to the aforementioned ideas for additional work, another direction for further investigations 544
is the application of the model framework to infectious episodes in immunocompromised individuals. 545
During the COVID-19 epidemic, immunocompromised individuals were a large cause for concern for 546
the creation of new variants due to their longer duration of infection [43–45]. To our knowledge, there 547
have been no reported cases of an immunocompromised individual being infected by H5N1 influenza, 548
and thus it is unclear how they would respond to the infection. As previously stated, the main cause 549
of death in those who contracted H5N1 influenza is currently believed to be cytokine storm. This 550
was also the leading cause of death from the Spanish flu epidemic in 1918-1920, but the fatality rate 551
was lower for the immunocompromised as they did not exhibit a sufficient immune response to cause 552
a cytokine storm [46, 47]. As a result, it may be that immunocompromised individuals are able to 553
sustain longer periods of infection, thus giving a larger probability of a human-to-human transmissible 554
strain mutating during their infection period. It is also possible that the virus simply overwhelms the 555
body of the immunocompromised, leading to rapid death, and thus little chance of producing mutant 556
strains of H5N1 influenza. Our current datasets are unable to distinguish between these possible 557
outcomes. The literature also shows that infections from H5N1 influenza can spread to other organs 558
and parts of the body [17]; it is likely that more detailed mortality modelling would need to take this 559
into account with different mortality modelling methods for immunocompromised people. 560

In this paper we have provided a model framework that gives the basis for the calculation of the 561
probability that the increased prevalence of influenza A(H5N1) in both birds and mammals leads 562
to a human infection that develops the ability for droplet transmission. These advancements in 563
modelling tools can help us determine how pandemic preparedness resources may be best focused 564
between infection directly from avian hosts or from mammalian hosts. Indeed, our process is not just 565
relevant to H5N1 influenza, but also for any pathogen for which within-host mutations are a concern. 566

Author contributions 567

Daniel Higgins: Data curation, Formal analysis, Investigation, Methodology, Software, Validation, 568
Visualisation, Writing - Original Draft, Writing - Review & Editing. 569

Josh Looker: Data curation, Formal analysis, Investigation, Methodology, Software, Validation, 570
Visualisation, Writing - Original Draft, Writing - Review & Editing. 571

Robert Sunnucks: Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualisation, Writing - Original Draft, Writing - Review & Editing. 572
573

Jonathan Carruthers: Conceptualisation, Methodology, Supervision, Visualisation, Writing - Review & Editing. 574
575

Thomas Finnie: Conceptualisation, Methodology, Supervision, Visualisation, Writing - Review & Editing. 576
577

Matt J. Keeling: Conceptualisation, Methodology, Supervision, Visualisation, Writing - Review & Editing. 578
579

Edward M. Hill: Conceptualisation, Methodology, Supervision, Visualisation, Writing - Review & Editing. 580
581

Financial disclosure 582

DH, LJ, RS and MJK were supported by the Engineering and Physical Sciences Research Council 583
through the MathSys CDT [grant number EP/S022244/1]. MJK was also supported by the Medical 584
Research Council through the JUNIPER partnership award [grant number MR/X018598/1]. EMH 585
is also linked with the JUNIPER partnership (MRC grant no MR/X018598/1) and would like to 586
acknowledge their help and support. EMH is supported by the NIHR Health Protection Research Unit 587
in Gastrointestinal Infections at the University of Liverpool (PB-PG-NIHR-200910), a partnership 588
with the UK Health Security Agency in collaboration with the University of Warwick. The research was 589
funded by The Pandemic Institute, formed of seven founding partners: The University of Liverpool, 590
Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City Council, 591
Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and 592
Knowledge Quarter Liverpool. EMH is based at The University of Liverpool. The views expressed are 593
those of the author(s) and not necessarily those of The Pandemic Institute. The funders had no role 594
in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 595
For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) 596
licence to any Author Accepted Manuscript version arising from this submission. 597

Data availability 598

All data utilised in this study are publicly available, with relevant references and data repositories 599
provided. 600

Code availability 601

The code repository for the study is available at: 602
`https://github.com/joshlooks/avianflu`. 603

Archived code available at:
`https://doi.org/10.5281/zenodo.13385416`.

Competing interests

All authors declare that they have no competing interests.

References

[1] World Health Organisation. The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention (2023). URL `https://www.who.int/publications/m/item/the-panzootic-spread-of-highly-pathogenic-avian-influenza-h5n1-sublineage-2.3.4.4b--a-critical-appraisal-of-one-health-preparedness-and-prevention`. [Online] (Accessed: 19 August 2024).

[2] Centres for Disease Control and Prevention (CDC). Past Reported Global Human Cases with Highly Pathogenic Avian Influenza A(H5N1) (HPAI H5N1) by Country, 1997-2024 (2024). URL `https://www.cdc.gov/bird-flu/php/avian-flu-summary/chart-epi-curve-ah5n1.html`. [Online] (Accessed: 19 August 2024).

[3] Sah R, Mohanty A, Rohilla R, Mehta R, Leon-Figueroa DA, *et al.* Human death due to H5N1 amid the COVID-19 pandemic and mpox outbreak: A call for action. *Int J Surg* **109**(3):576–578 (2023).

[4] World Health Organisation. Disease Outbreak News, Avian Influenza A(H5N1) - Vietnam (2024). URL `https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON511`. [Online] (Accessed: 19 August 2024).

[5] Centres for Disease Control and Prevention (CDC). Clinical Signs and Symptoms of Influenza (2022). URL `https://www.cdc.gov/flu/professionals/acip/clinical.htm`. [Online] (Accessed: 19 August 2024).

[6] Russell CA, Fonville JM, Brown AEX, Burke DF, Smith DL, *et al.* The Potential for Respiratory Droplet–Transmissible A/H5N1 Influenza Virus to Evolve in a Mammalian Host. *Science* **336**(6088):1541–1547 (2012). doi:10.1126/science.1222526.

[7] Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, *et al.* Exploring Cell Tropism as a Possible Contributor to Influenza Infection Severity. *PLOS ONE* **5**(11):1–15 (2010). doi:10.1371/journal.pone.0013811.

[8] Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, De Wit E, *et al.* Airborne transmission of influenza A/H5N1 virus between ferrets. *science* **336**(6088):1534–1541 (2012).

[9] Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, *et al.* Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. *Nature* **486**(7403):420–428 (2012).

[10] Kuchipudi SV, Nelli RK, Gontu A, Satyakumar R, Surendran Nair M, *et al.* Sialic Acid Receptors: The Key to Solving the Enigma of Zoonotic Virus Spillover. *Viruses* **13**(2) (2021). doi:10.3390/v13020262.

[11] World Health Organisation. Respiratory Infections (2024). URL `https://platform.who.int/mortality/themes/theme-details/topics/topic-details/MDB/respiratory-infections`. [Online] (Accessed: 19 August 2024).

[12] Ait Mahiout L, Bessonov N, Kazmierczak B, Volpert V. Mathematical modeling of respiratory viral infection and applications to SARS-CoV-2 progression. *Math Methods Appl Sci* (2022).

[13] Ciupe SM, Tuncer N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. *Sci Rep* **12**(1):14637 (2022).

[14] Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. *PLOS Computational Biology* **16**(4):1–29 (2020). doi:10.1371/journal.pcbi.1007705.

[15] Fonville JM, Burke DF, Lewis NS, Katzelnick LC, Russell CA. Quantifying the fitness advantage of polymerase substitutions in Influenza A/H7N9 viruses during adaptation to humans. *PLoS One* **8**(9):e76047 (2013).

[16] Fonville JM. Expected Effect of Deleterious Mutations on Within-Host Adaptation of Pathogens. *Journal of Virology* **89**(18):9242–9251 (2015). doi:10.1128/jvi.00832-15.

[17] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, *et al.* Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nature Medicine* **12**(10):1203–1207 (2006). doi:10.1038/nm1477.

[18] Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. *Journal of Theoretical Biology* **269**(1):234–244 (2011). doi:https://doi.org/10.1016/j.jtbi.2010.10.017.

[19] Handel A, Longini IM, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. *Journal of The Royal Society Interface* **7**(42):35–47 (2010). doi:10.1098/rsif.2009.0067.

[20] Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. *J Immunol* **172**(5):2731–2738 (2004).

[21] Perlman RL. Mouse models of human disease: An evolutionary perspective. *Evolution, Medicine, and Public Health* **2016**(1):170–176 (2016). doi:10.1093/emph/eow014.

[22] Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. *Journal of Clinical Bioinformatics* **2**(1):5 (2012). doi:10.1186/2043-9113-2-5.

[23] Ciupe SM, Tuncer N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. *Sci. Rep.* **12**(1):14637 (2022).

[24] Bocharov G, Romanyukha A. Mathematical model of antiviral immune response III. Influenza A virus infection. *Journal of Theoretical Biology* **167**(4):323–360 (1994).

[25] Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, *et al.* Modeling amantadine treatment of influenza a virus in vitro. *Journal of theoretical biology* **254**(2):439–451 (2008).

[26] Handel A, Longini Jr IM, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. *Journal of the Royal Society Interface* **7**(42):35–47 (2010).

[27] Minter A, Retkute R. Approximate Bayesian Computation for infectious disease modelling. *Epidemics* **29**:100368 (2019). doi:https://doi.org/10.1016/j.epidem.2019.100368.

[28] Filippi S, Barnes CP, Cornebise J, Stumpf MP. On optimality of kernels for approximate Bayesian computation using sequential Monte Carlo. *Statistical applications in genetics and molecular biology* **12**(1):87–107 (2013).

[29] Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP. Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. *Journal of the Royal Society Interface* **6**(31):187–202 (2009).

[30] Kogure T, Suzuki T, Takahashi T, Miyamoto D, Hidari KI, *et al.* Human trachea primary epithelial cells express both sialyl (α2-3) Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl (α2-6) Gal receptor for human influenza viruses. *Glycoconjugate journal* **23**:101–106 (2006).

[31] Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, *et al.* Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. *Journal of virology* **80**(15):7469–7480 (2006).

[32] Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus. *Journal of Virology* **80**(16):8060–8068 (2006). doi:10.1128/jvi.00384-06.

[33] Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, *et al.* Proinflammatory cytokine responses induced by influenza a (H5N1) viruses in primary human alveolar and bronchial epithelial cells. *Respir Res* **6**(1):135 (2005).

[34] Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cell Mol Immunol* **13**(1):3–10 (2015).

[35] Van Wesenbeeck L, D'Haese D, Tolboom J, Meeuws H, Dwyer DE, *et al.* A downward trend of the ratio of influenza RNA copy number to infectious viral titer in hospitalized influenza A-Infected patients. *Open Forum Infect Dis* **2**(4):ofv166 (2015).

[36] Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. *Journal of virology* **80**(15):7590–7599 (2006).

[37] Centres for Disease Control and Prevention (CDC). Current H5N1 Bird Flu Situation in Dairy Cows (2024). URL `https://www.cdc.gov/bird-flu/situation-summary/mammals.html`. [Online] (Accessed: 19 August 2024).

[38] Nasreen S, Khan SU, Luby SP, Gurley ES, Abedin J, *et al.* Highly pathogenic avian influenza A(H5N1) virus infection among workers at live bird markets, bangladesh, 2009-2010. *Emerg Infect Dis* **21**(4):629–637 (2015).

[39] Chen X, Wang W, Wang Y, Lai S, Yang J, *et al.* Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. *BMC Medicine* **18**(1):377 (2020). doi:10.1186/s12916-020-01836-y.

[40] Gomaa M, Moatasim Y, El Taweel A, Mahmoud SH, El Rifay AS, *et al.* We are underestimating, again, the true burden of H5N1 in humans. *BMJ Global Health* **8**(8) (2023). doi:10.1136/bmjgh-2023-013146.

[41] Smith JR. Oseltamivir in human avian influenza infection. *J Antimicrob Chemother* **65 Suppl 2**(Suppl 2):ii25–ii33 (2010).

[42] Couch RB, Davis BR. Has Oseltamivir been shown to be Effective for Treatment of H5N1 Influenza? *The Journal of Infectious Diseases* **202**(8):1149–1151 (2010). doi:10.1086/656317.

[43] Bansal N, Raturi M, Bansal Y. SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward. *Transfus Clin Biol* **29**(2):161–163 (2021).

[44] Ko KKK, Yingtaweesittikul H, Tan TT, Wijaya L, Cao DY, *et al.* Emergence of SARS-CoV-2 spike mutations during prolonged infection in immunocompromised hosts. *Microbiol Spectr* **10**(3):e0079122 (2022).

[45] Raglow Z, Surie D, Chappell JD, Zhu Y, Martin ET, *et al.* SARS-COV-2 shedding and evolution in patients who were immunocompromised during the Omicron period: A multicentre, prospective analysis. *The Lancet Microbe* **5**(3) (2024). doi:10.1016/s2666-5247(23)00336-1.

[46] Liu Q, Zhou Yh, Yang Zq. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cellular & Molecular Immunology* **13**(1):3–10 (2016). doi:10.1038/cmi.2015.74.

[47] Woo G. Age-dependence of the 1918 pandemic. *British Actuarial Journal* **24**:e3 (2019). doi:10.1017/S1357321719000023.

Supporting Information
Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans

Daniel Higgins[1,2‡*], Joshua Looker[1,2‡*], Robert Sunnucks[1,2‡*], Jonathan Carruthers[3], Thomas Finnie[3], Matt J. Keeling[2,4], Edward M. Hill[5,6*]

1 EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, United Kingdom.
2 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom.
3 Data, Analytics and Surveillance, UK Health Security Agency, London, United Kingdom.
4 Mathematics Institute and School of Life Sciences, University of Warwick, Coventry, United Kingdom.
5 Civic Health Innovation Labs and Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
6 NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, United Kingdom.

‡These authors contributed equally to this work.

* Corresponding Authors. Emails: daniel.higgins@warwick.ac.uk; joshua.looker@warwick.ac.uk; rob.sunnucks@warwick.ac.uk; edward.hill@liverpool.ac.uk.

Table of Contents

S1 Additional tables

Table S1. List of least-squares fit parameters: and their descriptions. Parameters fitted to the data in the log-space using the 'scipy.optimize' library in Python.

Parameter		Value
β_U	Rate of infection, URT	4.066×10^{-7}
β_L	Rate of infection, LRT	3.673×10^{-7}
p_U	Virus production rate, URT	0.2981
p_L	Virus production rate, LRT	9.641×10^{-2}
γ	Conversion between infectious virions and $TCID_{50}$ / PFU	3.459×10^{-3}
D	Rate of diffusion of free virions	0.2129
a	Rate of advection	0.1473

S2 Additional figures

(a)   **(b)**

Fig. S1. Posterior predictions for $v, r(t)$ assuming a lower case mortality rate (20% instead of 53%). Both plots show the 1000 posterior trajectories, with the blue lines representing H5N1 influenza patients who survive the infection (cleared the virus) and the red lines representing patients who died due to the infection (where the distinction is made using the method in Section 2.1.6). **(a)** Virion count distribution found using the parameter posterior in Fig. 4. The viral count trajectories for deceased patients are lower and more sustained than surviving patients. These were calculated from the one million BPM realisations each with an initial viral load of 10^6 and a mutation chance of 10^{-5} per replication. **(b)** Distribution of $r(t)$ calculated from the posterior predictive distribution shown in Fig. 5(a). Surviving patients tended to have higher $r(t)$ in the first 4 days of infection, which then declined below one (indicating a decreasing virion count) more rapidly than for dying patients.

Fig. S2. Maximum r value vs viral lifespan assuming a lower case mortality rate (20% instead of 53%). We observe a strong negative correlation between maximum r value and the viral lifespan. Maximum r values taken from Fig. 6(b) and corresponding viral lifespans are shown in Fig. 3. Blue circles represent H5N1 influenza patients who survive the infection (cleared the virus). Red circles represent patients who died due to the infection (where the distinction is made using the method in Section 2.1.6). Surviving individuals tended to have higher maximum $r(t)$ values.

Fig. S3. Mutated virion statistics with respect to time elapsed post infection, computed from BPM realisations assuming a lower case mortality rate (20% instead of 53%). Line shading corresponds to the number of mutations (one mutation the lightest shading through to five mutations being the darkest shading). In all BPM simulations we fixed the probability of mutation at 10^{-5} per replication. In panels **(a&b)**, each realisation had an initial viral load of 10^6. We ran 1000 realisations of each of the 1000 posterior parameter sets (Fig. 4). In panels **(c&d)**, each realisation had an initial viral load of $10^6 \times 10^6$. We ran one realisation of each of the 1000 posterior parameter sets (Fig. 4). **(a,c)** Proportion of total virions with the specified amount of mutations. There were a very small proportion of virions that have the required number of mutations to achieve droplet transmission (three or more mutations). **(b,d)** Probability of having a mutation strain. We present the estimated probabilities as the dashed lines with circle markers. We present the actual probabilities as solid lines. Probability estimate derivation follows that given in Section 2.2. The estimated probabilities are a clear upper bound on the true probabilities. Depending on the number of mutations in the initial infecting virions, there was a low probability of achieving the required number of mutations near the beginning on the infection lifespan (which would allow more replication of the mutant strains).